Cargando…
Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold
(1) Background: In the development of new and more effective anticancer approaches, combined treatments appear of great interest. Combination therapy could be of importance in the management of glioblastoma (GBM), a lethal malignancy that accounts for 42% of cancer of the central nervous system, wit...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181338/ https://www.ncbi.nlm.nih.gov/pubmed/35682670 http://dx.doi.org/10.3390/ijms23115991 |
_version_ | 1784723747018637312 |
---|---|
author | Zurlo, Matteo Romagnoli, Romeo Oliva, Paola Gasparello, Jessica Finotti, Alessia Gambari, Roberto |
author_facet | Zurlo, Matteo Romagnoli, Romeo Oliva, Paola Gasparello, Jessica Finotti, Alessia Gambari, Roberto |
author_sort | Zurlo, Matteo |
collection | PubMed |
description | (1) Background: In the development of new and more effective anticancer approaches, combined treatments appear of great interest. Combination therapy could be of importance in the management of glioblastoma (GBM), a lethal malignancy that accounts for 42% of cancer of the central nervous system, with a median survival of 15 months. This study aimed to verify the activity on a glioblastoma cancer cell line of one of the most active compounds of a novel series of tubulin polymerization inhibitors based on the 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1H-imidazole scaffold, used in combination with a miRNA inhibitor molecule targeting the oncomiRNA miR-10b-5p. This microRNA was selected in consideration of the role of miR-10b-5p on the onset and progression of glioblastoma. (2) Methods: Apoptosis was analyzed by Annexin-V and Caspase 3/7 assays, efficacy of the anti-miR-10b-5p was assessed by determining the miR-10b-5p content by RT-qPCR. (3) Results: The results obtained show that a “combination therapy” performed by combining the use of an anti-miR-10b-5p and a 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1H-imidazole derivative is an encouraging strategy to boost the efficacy of anticancer therapies and at the same time to reduce side effects. |
format | Online Article Text |
id | pubmed-9181338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91813382022-06-10 Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold Zurlo, Matteo Romagnoli, Romeo Oliva, Paola Gasparello, Jessica Finotti, Alessia Gambari, Roberto Int J Mol Sci Article (1) Background: In the development of new and more effective anticancer approaches, combined treatments appear of great interest. Combination therapy could be of importance in the management of glioblastoma (GBM), a lethal malignancy that accounts for 42% of cancer of the central nervous system, with a median survival of 15 months. This study aimed to verify the activity on a glioblastoma cancer cell line of one of the most active compounds of a novel series of tubulin polymerization inhibitors based on the 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1H-imidazole scaffold, used in combination with a miRNA inhibitor molecule targeting the oncomiRNA miR-10b-5p. This microRNA was selected in consideration of the role of miR-10b-5p on the onset and progression of glioblastoma. (2) Methods: Apoptosis was analyzed by Annexin-V and Caspase 3/7 assays, efficacy of the anti-miR-10b-5p was assessed by determining the miR-10b-5p content by RT-qPCR. (3) Results: The results obtained show that a “combination therapy” performed by combining the use of an anti-miR-10b-5p and a 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1H-imidazole derivative is an encouraging strategy to boost the efficacy of anticancer therapies and at the same time to reduce side effects. MDPI 2022-05-26 /pmc/articles/PMC9181338/ /pubmed/35682670 http://dx.doi.org/10.3390/ijms23115991 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zurlo, Matteo Romagnoli, Romeo Oliva, Paola Gasparello, Jessica Finotti, Alessia Gambari, Roberto Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold |
title | Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold |
title_full | Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold |
title_fullStr | Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold |
title_full_unstemmed | Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold |
title_short | Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold |
title_sort | synergistic effects of a combined treatment of glioblastoma u251 cells with an anti-mir-10b-5p molecule and an anticancer agent based on 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1h-imidazole scaffold |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181338/ https://www.ncbi.nlm.nih.gov/pubmed/35682670 http://dx.doi.org/10.3390/ijms23115991 |
work_keys_str_mv | AT zurlomatteo synergisticeffectsofacombinedtreatmentofglioblastomau251cellswithanantimir10b5pmoleculeandananticanceragentbasedon1345trimethoxyphenyl2aryl1himidazolescaffold AT romagnoliromeo synergisticeffectsofacombinedtreatmentofglioblastomau251cellswithanantimir10b5pmoleculeandananticanceragentbasedon1345trimethoxyphenyl2aryl1himidazolescaffold AT olivapaola synergisticeffectsofacombinedtreatmentofglioblastomau251cellswithanantimir10b5pmoleculeandananticanceragentbasedon1345trimethoxyphenyl2aryl1himidazolescaffold AT gasparellojessica synergisticeffectsofacombinedtreatmentofglioblastomau251cellswithanantimir10b5pmoleculeandananticanceragentbasedon1345trimethoxyphenyl2aryl1himidazolescaffold AT finottialessia synergisticeffectsofacombinedtreatmentofglioblastomau251cellswithanantimir10b5pmoleculeandananticanceragentbasedon1345trimethoxyphenyl2aryl1himidazolescaffold AT gambariroberto synergisticeffectsofacombinedtreatmentofglioblastomau251cellswithanantimir10b5pmoleculeandananticanceragentbasedon1345trimethoxyphenyl2aryl1himidazolescaffold |